674 related articles for article (PubMed ID: 17146784)
1. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma.
Paek SC; Griffith KA; Johnson TM; Sondak VK; Wong SL; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2007 Jan; 109(1):100-8. PubMed ID: 17146784
[TBL] [Abstract][Full Text] [Related]
2. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
[TBL] [Abstract][Full Text] [Related]
3. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
4. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
5. Do micromorphometric features of metastatic deposits within sentinel nodes predict nonsentinel lymph node involvement in melanoma?
Frankel TL; Griffith KA; Lowe L; Wong SL; Bichakjian CK; Chang AE; Cimmino VM; Bradford CR; Rees RS; Johnson TM; Sabel MS
Ann Surg Oncol; 2008 Sep; 15(9):2403-11. PubMed ID: 18626721
[TBL] [Abstract][Full Text] [Related]
6. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma.
Statius Muller MG; van Leeuwen PA; de Lange-De Klerk ES; van Diest PJ; Pijpers R; Ferwerda CC; Vuylsteke RJ; Meijer S
Cancer; 2001 Jun; 91(12):2401-8. PubMed ID: 11413531
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
8. Sentinel lymph node biopsy in melanoma: a micromorphometric study relating to prognosis and completion lymph node dissection.
Debarbieux S; Duru G; Dalle S; Béatrix O; Balme B; Thomas L
Br J Dermatol; 2007 Jul; 157(1):58-67. PubMed ID: 17501957
[TBL] [Abstract][Full Text] [Related]
9. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
[TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
[TBL] [Abstract][Full Text] [Related]
11. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
[TBL] [Abstract][Full Text] [Related]
12. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma.
Sabel MS; Griffith K; Sondak VK; Lowe L; Schwartz JL; Cimmino VM; Chang AE; Rees RS; Bradford CR; Johnson TM
J Am Coll Surg; 2005 Jul; 201(1):37-47. PubMed ID: 15978442
[TBL] [Abstract][Full Text] [Related]
13. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
14. An increased number of sentinel lymph nodes is associated with advanced Breslow depth and lymphovascular invasion in patients with primary melanoma.
Schmidt CR; Panageas KS; Coit DG; Patel A; Brady MS
Ann Surg Oncol; 2009 Apr; 16(4):948-52. PubMed ID: 19194758
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors of cutaneous melanoma in relation to metastasis at the sentinel lymph node: a case-controlled study.
Sartore L; Papanikolaou GE; Biancari F; Mazzoleni F
Int J Surg; 2008 Jun; 6(3):205-9. PubMed ID: 18417434
[TBL] [Abstract][Full Text] [Related]
16. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients.
Roka F; Mastan P; Binder M; Okamoto I; Mittlboeck M; Horvat R; Pehamberger H; Diem E
Eur J Surg Oncol; 2008 Jan; 34(1):82-8. PubMed ID: 17360144
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of anatomic location of primary cutaneous melanoma of 1 mm or thicker.
Callender GG; Egger ME; Burton AL; Scoggins CR; Ross MI; Stromberg AJ; Hagendoorn L; Martin RC; McMasters KM
Am J Surg; 2011 Dec; 202(6):659-64; discussion 664-5. PubMed ID: 22137134
[TBL] [Abstract][Full Text] [Related]
18. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma.
Murali R; Haydu LE; Quinn MJ; Saw RP; Shannon K; Spillane AJ; Stretch JR; Thompson JF; Scolyer RA
Ann Surg; 2012 Jan; 255(1):128-33. PubMed ID: 21975320
[TBL] [Abstract][Full Text] [Related]
19. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.
Kesmodel SB; Karakousis GC; Botbyl JD; Canter RJ; Lewis RT; Wahl PM; Terhune KP; Alavi A; Elder DE; Ming ME; Guerry D; Gimotty PA; Fraker DL; Czerniecki BJ; Spitz FR
Ann Surg Oncol; 2005 Jun; 12(6):449-58. PubMed ID: 15864482
[TBL] [Abstract][Full Text] [Related]
20. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma.
Vuylsteke RJ; Borgstein PJ; van Leeuwen PA; Gietema HA; Molenkamp BG; Statius Muller MG; van Diest PJ; van der Sijp JR; Meijer S
Ann Surg Oncol; 2005 Jun; 12(6):440-8. PubMed ID: 15864481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
